Record margins backed by customer commitments; FY28 guide raised to ₹1,600 Cr
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 7/10
Grade B
Hit quarterly earnings targets precisely; raised FY28 guide. But Q1 margin is at upper bound (17-20% was prior range); supply chain headwinds emerging.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Strong Q1 delivered ₹308 Cr revenue (+55% YoY) with 24.2% EBITDA margin, anchored by customer commitments and capacity leverage. FY28 guidance raised to >₹1,600 Cr. However, margin at historical high is vulnerable to supply shocks (raw material delays, shipping congestion acknowledged); execution risk on ₹250 Cr CAPEX ramp (Q1 & Q4 FY28) is material.
₹307.7 Cr
Revenue · +54.9% YoY₹36.1 Cr
Reported PAT · +889.2% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Highest quarterly revenue of ₹308 Cr, 42% volume growth YoY
MET₹307.7 Cr revenue delivered; YoY growth 54.9% but management attributes 42% to volume, balance to price/mix
EBITDA margin improved from 17% to 24%
METEBITDA ₹74.42 Cr on ₹307.7 Cr revenue = 24.2% — confirmed. Prior year margin was ~17%; this is +720 bps
Confident to sustain 24% EBITDA margin going forward
OVERSTATEDMargin achieved via 65% utilization (up from 50%), product mix, and customer commitments. However, 24% is at historical high; supply chain stress acknowledged; maintenance (not growth) now guided
Revenue from new products contributes ~30% of mix over last 2 years
METCompany grew from ₹600 Cr to ₹850 Cr YoY; ~30% uplift attributed to new chemistry. Corroborated in call
Long-term contracts now 50%+ of revenue (vs. prior 30-40% spot pricing)
METManagement stated moved from 30-40% long-term to 50%+. Formula-driven pricing mitigates volatility risk
Earnings quality
What changed since the last call
FY28 revenue guidance raised to >₹1,600 Cr
UpgradePrior Q4 FY26 call indicated ₹1,500 Cr FY28 target. Now raised >₹1,600 Cr, driven by customer commitments + CAPEX ramp visibility + long-term contracts at 50% mix.
FY27 CAPEX doubled to ₹250 Cr
UpgradePlan was ₹125 Cr; revised ₹250 Cr for two new production buildings at Pakhajan. Targets ₹500-600 Cr revenue potential (2.5x turns).
Margin guidance from 17-20% range to 24% sustainable
UpgradeAnalysts Parth Agrawal challenged: historically guided 17-20%, now at 24% and managing confidence. Parag clarified leverage (50% → 65%), product mix, R&D, customer commitments. But framing shifted to 'maintain' not 'grow' margin going forward.
Long-term contract mix increased to 50%+
UpgradePrior 30-40% spot pricing. Now 50%+ on quarterly/6-month/yearly formula basis. Mitigates price volatility, stabilizes EBITDA %.
The Q&A
Q&A was robust. Parth Agrawal pressed on margin sustainability (17-20% historical vs. 24% now) — Parag provided 3-factor explanation (leverage, mix, commitments) but analysts skeptical. Lovish Soien drilled into new-product margins (+10-12%) and spot-pricing decline, suggesting multiple tailwinds may be temporary. Aman Thadani flagged supply chain stress (raw material delays, container booking challenges) — Parag conceded 'genuine supply issue', 'struggling lot for day to day.' Management held up well on facts but tone cautious on forward margin uplift.
Margin sustainability — Meet Katrodiya, Niveshaay
AnsweredCompany achieved this via right product mix, capacity utilization 50%→65%, NOT old stock. Marquee customer commitments backing confidence on sustaining EBITDA margins in coming quarters.
Volume growth quality — Meet Katrodiya, Niveshaay
PartialCustomer commitment in place; expecting similar growth in coming quarters. Volumes should grow.
Export geographies — Meet Katrodiya, Niveshaay
AnsweredStill developing market, early inroads, customer acceptance good. Margins at par or slightly lower, nothing alarming.
Export mix trajectory — Meet Katrodiya, Niveshaay
AnsweredCorrected analyst: targeting 70-75%, not 85-90%. No presumptions, grounded forecast only.
CAPEX and new facility — Nishita Shanklesha, Sapphire Capital
PartialIndustrial chemicals (existing + new). Peak potential mentioned ₹800 Cr at March 2026 base, FY28 guidance ₹1,600+ Cr. Phase-1 (Q1 FY28) ₹100 Cr, Phase-2 (Q4 FY28) ₹150 Cr. Ramp ~15 months from here.
Margin drivers — Parth Agrawal, Bastion Research
AnsweredThree factors: (1) Leverage — 50% → 65% utilization; (2) Customer offtake increase; (3) Product mix. R&D support and process optimization underlying. Multiple factors at play.
New molecules commercialization — Pujan Shah, Molecule Venture
AnsweredInitially in ₹50-100 Cr range. For CAPEX, yes, 2.5x assumption fair. New facility combined capacity will maintain 70-75% utilization healthy run rate.
Competitive risk (China capacity) — Pujan Shah, Molecule Venture
Partial¥12-15 Bn addressable market; aspiring to $200-300 Mn. Not aiming for $500Mn-$1 Bn immediately. Customers seek alternate supply chains. Not a challenge.
Price realization track record — Pujan Shah, Molecule Venture
AnsweredQuarterly pricing with customers wherever applicable. Negotiated better with customers in Q1 based on raw material direction hints. Price stable April-June.
Utilization sustainability — Amar Maurya, Lucky Investment
PartialGrowing QoQ but no unit-wise number. Company-level utilization target 75% FY27. Won't speculate on Pakhajan solo.
Volume sustainability — Amar Maurya, Lucky Investment
AnsweredEBITDA percentage constant, not per kg. Formula-driven pricing with customers; price up = better realization, price down = reduce price. Simple theory.
New products contribution — Disha Chamriya, Trinetra Asset Managers
AnsweredGained ~30% revenue contribution from new product line over last 2 years (₹600 Cr → ₹850 Cr). Expecting ramp up further. All incremental growth from new chemistry.
Customer concentration — Disha Chamriya, Trinetra Asset Managers
AnsweredTop customer ~7% of revenue. No customer list disclosed.
EV risk to lubricants — Jainam Mandrecha, C9 Family Office
PartialEV could be fit after 15-20 years. 10-year horizon, not a threat. Major growth from existing products, few new. Product mix and churning helping. Leverage from 65% → 75% will improve margins further.
Price volatility in growth guide — Rohit Sinha, Sunidhi Securities
AnsweredGrowth now contractual long-term not spot. Formula-based, margins remain stable. Contract types: evergreen (ongoing), 3-6 month pricing, or fixed 1-2 year tenure.
Margin expansion room — Rohit Sinha, Sunidhi Securities
AnsweredEffort to achieve better, but can't promise. Tomorrow's crises unknown. Prefer to maintain margin next 2-3 years; then discuss growth.
R&D and customer acquisition — Shivam Vashi, Inga Ventures
AnsweredR&D backbone of company. Shut Vapi R&D, pivoted all to Pakhajan. Started pilot facility. Lots of customer requests + new customers coming based on chemistry profile. Marquee customers attracted by Pakhajan facility + R&D + turnaround.
Margin differential of new products — Lovish Soien, Burman Capital
AnsweredYes, products in last 12 months have better margin + higher offtake. Differential ~10-12% better than old products. Mix + utilization driving improvement.
Long-term contract mix impact — Lovish Soien, Burman Capital
AnsweredPast 30-40% long-term, now 50%+. Formula pricing mitigates volatility.
Supply chain risk — Aman Thadani, Solidarity Investment Managers
AnsweredInventory down but due to supply issues on raw material side. Genuine supply issue. Export booking challenges (wait 3-4 weeks for containers, not enough ships/booking). Logistics team struggling. Our team working hard but struggling day-to-day.
Market share gains — Aman Thadani, Solidarity Investment Managers
AnsweredDon't know whom we're replacing. USA market gaining (tariff issues gone, sales up sizably). Middle East, Europe growing well. Making inroads into Asian/African markets dominated by Asian players.
FY28 guidance exclusivity — Subhanu, 3X Capital
AnsweredYes, ₹1,600+ Cr excludes prior ₹125 Cr. For ₹250 Cr CAPEX: 2.5x asset turn.
Domestic growth segment — Subhanu, 3X Capital
AnsweredDomestic ~10% growth. Major growth from export.
FY28 facility ramp contribution — Dakshesh Gupta, Individual Investor
PartialWill try our best to get that.
Customer bookings for new capacity — Dakshesh Gupta, Individual Investor
AnsweredUp to 60-65% we have customers. To balance, need to search.
Broader growth strategy beyond lube — Rikin Shah, Boring AMC
AnsweredNot lube alone. Mix of industrial chemicals. Lube significant but not only segment. Diversification helps sustain (specialty → food → aroma → rubber → lubricant → now split into two). Works as hedge if one segment hit.
Guidance
FY28 revenue >₹1,600 Cr (raised from ₹1,500 Cr prior guidance)
HighBacked by marquee customer commitments (disclosed long-term agreement + other NDA-protected contracts). ₹250 Cr CAPEX provides 2.5x asset turn potential (₹500-600 Cr new revenue). 65% of CAPEX capacity already booked.
Endeavor to maintain 24% EBITDA margin in FY27-FY28 going forward
MediumBased on continued 70-75% utilization, customer commitment lock-in, and long-term formula pricing. Supply chain headwinds (raw material delays, export booking stress) introduce volatility. Management conservative: 'will try' not 'will achieve'.
FY27 CAPEX ₹250 Cr (raised from ₹125 Cr), split Phase-1 ₹100 Cr (Q1 FY28), Phase-2 ₹150 Cr (Q4 FY28)
HighTwo production buildings at Pakhajan facility. Supporting infrastructure in place. Ramp-up ~15 months from now. Funding via ₹100 Cr borrowings expected in FY27.
Risks the call surfaced
Supply chain disruption
HighManagement conceded 'genuine supply issue on raw material side', 'export container booking challenges' (wait 3-4 weeks), 'not enough ships available'. Inventory cycle down 190 → 143 days partly due to supply constraints, not pure WC optimization.
Margin sustainability risk
High24% EBITDA margin is highest in 8+ years; historically guided 17-20%. Achieved via 3 levers: (1) leverage (50%→65%), (2) product mix (+10-12% new products), (3) customer commitments. All three are time-bound or demand-dependent. Spot pricing still 50%; price volatility risk.
CAPEX execution risk
High₹250 Cr CAPEX critical to FY28 guidance. Two-phase: Phase-1 (₹100 Cr, Q1 FY28), Phase-2 (₹150 Cr, Q4 FY28). ~15 months construction + machinery erection + stabilization. 65% capacity pre-booked, but remaining 35% demand-dependent. If ramp delayed or underutilized, ₹1,600 Cr guidance at risk.
Tariff and geopolitical exposure
MediumExport 69% of revenue; USA tariffs were headwind (now removed), USA subsidiary recovering. But tariffs could return. Europe exposure to Russia/Ukraine. Middle East/Africa expansion nascent. FX swings (INR vs. USD) not hedged on call.
EV and ICE transition risk
LowJainam Mandrecha flagged ICE-dependent lubricant business faces terminal risk from EV growth. Management downplayed: 'EV could be fit after 15-20 years. In 10 years' horizon, not a threat.' But lube segment is legacy; new molecules + industrial chemicals are hedge. Minority of portfolio now.
Management
Score 7/10. Clear, data-driven, transparent on constraints. MD Parag Jhaveri doesn't over-assert; uses 'will try' on margin targets, not 'will achieve'. Willing to disclose supply chain stress (container booking, raw material delays). Refuses to disclose individual plant utilization (Pakhajan) — draws line on competitive info. CFO Chirag Shah precise on numbers (EBITDA ₹74.42 Cr, debt ratios exact). Some deflection on customer names (NDA cited). Met FY26 guidance; volumes 42% (within 35-45% prior range), margins 24% (beat 20% low end), FY28 raised to ₹1,600+ Cr vs. ₹1,500 Cr prior. Rating upgrades (BBB+ → A-) validate deleveraging. Working capital cycle improved meaningfully (190 → 143 days). However, supply chain headwinds emerging real-time; execution risk on CAPEX ramp high.
1 · Q1 FY28
Phase-1 new production building (₹100 Cr CAPEX) at Pakhajan facility commissioned. Revenue potential ~₹200 Cr at 2x asset turn.
2 · Q1 FY28
Long-term supply agreement commercialization expected; management guided on track per execution schedule.
3 · Q4 FY28
Phase-2 production building (₹150 Cr CAPEX) expected operational, completing ₹250 Cr facility investment.
However, margin at historical high is vulnerable to supply shocks (raw material delays, shipping congestion acknowledged); execution risk on ₹250 Cr CAPEX ramp (Q1 & Q4 FY28) is material.
Record EBITDA margin comes with a supply chain tail risk
Yasho delivered ₹308 Cr revenue and 24.2% EBITDA margins—both at highs—but the earnings call reveals the quarter sits atop three fragile levers: leverage, product mix, and customer commitments. Supply chain stress is emerging real-time.
₹308 Cr
+55% YoY; volume +42%, price/mix +13%
₹74.4 Cr
+106% YoY; margin 24.2% vs. prior 17%
65%
+1,500 bps YoY; target 75% FY27
1.86x
down from 3.75x Q4; improved deleveraging
The real story: margin at an inflection point
On the surface, Yasho Industries delivered what the market wanted to see: ₹308 crore revenue (+55% YoY), ₹36.1 crore net profit (+889% YoY), and a record EBITDA margin of 24.2%—a jump of 720 basis points from the prior year's 17%. Rating upgrades followed (CRISIL/ICRA moved to A-). But the earnings call exposed the real tension: this 24.2% margin is at the company's 8-year high, resting on three temporary levers that analysts pressed management hard to defend.
Where the margin came from
Management attributed the +720 bps margin jump to three factors. First, capacity leverage: utilization climbed from 50% to 65% at the Pakhajan facility, driving fixed-cost absorption. Second, product mix: new-chemistry products launched in the prior 24 months now contribute ~30% of revenue and carry 10–12% higher margins than legacy lines. Third, long-term customer contracts: the company shifted 50%+ of revenue mix into quarterly/6-month/yearly formula-based pricing (up from 30–40% spot), which locks in pass-through economics and reduces spot-price volatility. The arithmetic is clean—volume +42%, price/mix contributing ~13% of the 55% revenue growth—but the sustainability question is whether all three levers remain in place simultaneously.
Highest quarterly revenue ₹308 Cr, 42% volume growth YoY
₹307.7 Cr revenue; volume confirmed +42%; price/mix ~+13%
Supported
EBITDA margin improved from 17% to 24.2%; confident to sustain
Achieved via 65% util (from 50%), product mix, customer lock-in. But supply chain headwinds emerging; tone shifted to 'endeavor' not 'achieve'
Overstated
Revenue from new products ~30% of mix over last 2 years
Company grew ₹600 Cr → ₹850 Cr YoY; ~30% uplift attributed to new chemistry
Supported
Long-term contracts now 50%+ of revenue (vs. prior 30–40% spot)
Management confirmed moved to 50%+ formula-driven pricing
Supported
Can maintain 24% EBITDA margin going forward
Management: 'will endeavor to maintain'—but conceded supply chain stress (raw material delays, export container booking 3–4 week waits). Margin at historical high is vulnerable to input-cost pass-through lag
Overstated; conditional at best
What changed on this call
Yasho raised two critical guidances. FY28 revenue target lifted to >₹1,600 crore (from ₹1,500 Cr prior guidance). CAPEX doubled to ₹250 crore (from ₹125 Cr plan), split into two phases: ₹100 Cr in Phase-1 (commissioning Q1 FY28) and ₹150 Cr in Phase-2 (Q4 FY28) for production buildings at Pakhajan. Management projects these assets will generate 2.5x asset turns—implying ~₹500–600 Cr in incremental revenue potential. Critically, 60–65% of the new capacity is already pre-booked by marquee customers via long-term agreements (exact customer names under NDA). The long-term contract mix itself grew from 30–40% spot-pricing to 50%+, a structural shift toward price stability. These moves are bullish on the surface—a clear growth plan backed by customer commitments—but also signal management's intent to lock in customers before execution risk on the CAPEX ramp plays out.
Bull-bear ledger
Record quarterly revenue ₹308 Cr; highest in company history
EBITDA margin 24.2% at 8-year peak; upgrades validate track record (BBB+ → A-)
FY28 guidance >₹1,600 Cr backed by marquee customer commitments and concrete CAPEX plan
Long-term contracts now 50%+ of mix; reduces spot-price volatility and stabilizes margins
New-product chemistry now 30% of revenue with 10–12% margin premium; R&D pipeline validated
24% EBITDA margin is at historical high; three levers (leverage, mix, commitments) are time-bound or demand-dependent
Supply chain headwinds acknowledged (raw material delays, export logistics stress); margin pass-through lag risk
50% of revenue still on spot pricing; exposed to commodity cycles if tariffs return or geopolitical shock hits
CAPEX ramp timing critical (Q1 & Q4 FY28); 35% of new capacity still to find customers; execution risk material
Analysts (Parth Agrawal, Lovish Soien) pushed hard on margin sustainability; management tone cautious ('endeavor', not 'achieve')
Risks ranked by materiality
Margin sustainability at cyclical peak
High24.2% EBITDA at 8-year high; three levers (capacity leverage to 65%, product mix +10–12%, customer lock-in) compound simultaneously but are time-bound. Historical guidance was 17–20%. If supply costs inflate suddenly, formula pricing resets only quarterly; margin squeeze likely mid-quarter. Management framing shifted to 'maintain' not 'grow'—a red flag on confidence.
Supply chain disruption (real-time)
HighRaw material procurement delays, export container booking stress (3–4 week waits, 'not enough ships'), and logistics team 'struggling day-to-day'. Spot-pricing (50% of revenue) exposed to tariff re-entry (USA tariff reprieve is recent). Long-term formula contracts mitigate but lag pass-through. A macro shock (renewed tariffs, shipping crisis, geopolitical escalation) would compress margins in near term.
CAPEX execution and utilization
HighFY28 guidance >₹1,600 Cr depends on ₹250 Cr CAPEX ramp (Phase-1 Q1 FY28, Phase-2 Q4 FY28). 60–65% pre-booked; 35–40% capacity to find. Ramp timing ~15 months; any delay pushes revenue recognition into FY29. Utilization miss (if demand softens or onboarding slips) would sink ROI on the ₹250 Cr capex.
Spot-pricing exposure and geopolitical volatility
Medium50% of revenue still on quarterly spot pricing. USA (recovering from tariff impact, now 'gaining quite well'), Europe (stable), ME/Africa (emerging). If tariffs re-emerge, USA sales could reverse. FX volatility (INR vs. USD) on call unhedged. Export 69% of revenue; macro softness (autos, chemicals demand) would impact OEM offtake.
EV transition risk (tail)
LowLubricant segment (part of industrial chemicals 89% mix) ICE-dependent. Management downplayed: 'EV could fit after 15–20 years; in 10-year horizon, not a threat.' But lube margins could compress in 5–10 years if EV adoption accelerates. Diversification into specialty chemicals, rubber, performance segments is a hedge, but still a secular headwind.
How the street is positioned
The stock reacted strongly to the result: day-1 pop +0.68%, accelerating to +7.74% by day-3 and +8.2% by day-5 post-announcement. That 8.2% move has held, confirming the market's fundamental read on the earnings beat and guidance raise. However, RSI at 78 signals overbought territory—a typical warn flag for caution on further upside without a pullback. The stock now trades ₹4,175, sitting 269% above its 52-week low (₹1,130) but 7% below its all-time high (₹4,489.50). It trades comfortably above all major moving averages (SMA20 ₹3,393, SMA50 ₹2,990, SMA200 ₹1,878), confirming an established uptrend but also suggesting limited margin of safety at current levels.
Institutional positioning is modest. FII ownership held flat (5.74% in Q1 FY27 vs. 5.71% in Q4), suggesting institutions are neither adding heavily nor retreating post-result. DII inflows were marginal (+0.24pp to 2.21%). Promoter stake remained stable at 67.94%. The absence of aggressive institutional accumulation on the back of this beat is notable—it suggests the market is pricing in the margin and CAPEX risks already, or waiting for Q2 proof-of-concept on margin sustenance before committing fresh capital.
What to watch next
1 · Q2 EBITDA margin (the number to track)
Will 24% hold or pull back? If supply-chain pass-through lags and spot-pricing compresses, expect margin to fall to 22–23% in Q2. Management will guide; analysts will parse whether the move is temporary or structural. This single metric settles the debate on margin sustainability.
2 · Phase-1 CAPEX progress (Q1 FY28 commissioning timeline)
Does the ₹100 Cr Phase-1 production building start on schedule? Any delay pushes FY28 revenue recognition into later quarters. Customer offtake and ramp-up speed (target: ₹100+ Cr revenue from Phase-1 in FY28 implies 2.5x asset turn, a stretch if utilization stalls). Watch for Q2 management commentary on procurement and construction milestones.
3 · Spot-pricing resilience and tariff re-entry risk
USA tariff reprieve has boosted sales 'quite well'; if tariffs re-emerge or geopolitical shock disrupts shipping, USA revenue reverses. Monitor quarterly export mix and USA subsidiary revenue. A softening in USA or Europe (30–40% of export base combined) would signal macro headwinds compressing offtake.
Yasho Industries delivered a record quarter—₹308 Cr revenue, 24.2% EBITDA margin, FY28 guidance >₹1,600 Cr, and concrete CAPEX to back it. But the call revealed the margin sits atop three levers that are either time-bound (capacity leverage), temporary (product mix cycle), or demand-dependent (customer commitments). Supply chain stress is live. The honest read is not a step-change in business quality, but a strong cyclical peak with execution and macro risk. The margin holds the answer. Track Q2 EBITDA as the single most important metric from here—if it remains above 23%, the bull case survives; if it falls below 21%, cyclical-peak fears are validated. The street's overbought RSI and modest institutional inflows both suggest this is a hold-and-watch, not a buy-on-dip situation.
Yasho Q1: consolidated PAT ₹36 Cr on 11.7% margin as exports drive 55% YoY revenue jump
PAT +889.2% YoY · revenue +54.93% · margins expanding · beat vs street
₹307.74 Cr
+54.93% YoY
₹36.05 Cr
+889.2% YoY
11.66%
+9.8pp YoY
₹29.9
Yasho Industries opened FY27 with its strongest quarter on record. Consolidated revenue rose ~55% YoY to ₹307.7 Cr (from ₹198.6 Cr) and ~25% QoQ, while net profit multiplied nearly 10x to ₹36.1 Cr from a depressed ₹3.6 Cr year-ago base — the print's headline growth is real but flattered by that weak Q1 FY26 comparator, so the margin story matters more than the raw multiple. Net margin expanded to 11.7% from 1.8% a year ago and 5.0% last quarter, and EBITDA margin lifted to roughly 24% versus ~16% YoY, showing genuine operating leverage rather than a one-off; there were no exceptional items on either side, so no adjustment to growth is required.
Q1 FY-2027 vs prior quarters
The swing was driven by exports and operating leverage. Group sales outside India jumped to ₹214.8 Cr from ₹135.9 Cr YoY (now ~70% of the mix), and gross margins improved as a large inventory build (₹36.2 Cr change in stock) absorbed material cost, while finance costs eased to ₹11.3 Cr from ₹13.8 Cr. Against the Street, the print is a clear beat: brokerage previews (Univest/Uniresearch) modelled Q1 revenue of ₹246–283 Cr, and the actual ₹307.7 Cr cleared the top of that range. It also validates management's May concall guidance — 35–45% FY27 volume growth and EBITDA margins at 20%+ — with this quarter already running above the margin target and revenue growth ahead of the volume guide (helped by price/mix).
The stock went into the print at ₹3,815.9, up 29.1% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
Management provided an optimistic outlook for FY27, projecting a volume growth of 35%-45% driven by a 15% increase in capacity utilization. They anticipate EBITDA margins to improve to 20% or higher, aided by operational efficiencies and cost optimization. The company is guiding for INR1,500 crores in revenue by FY28,
— This quarter: beat
Alongside results, the board moved to fund the next leg of expansion: it approved raising borrowing limits from ₹750 Cr to ₹1,250 Cr (subject to shareholder approval), consistent with the ₹125 Cr FY27 capex earmarked for the Pakhajan plant and the FY28 ₹1,500 Cr revenue ambition underpinned by a long-term contract due to commercialise in FY28. Standalone and consolidated tell a very similar story here (both ~₹36 Cr PAT), so the group number is not distorted by the subsidiaries despite their thin standalone profitability. The earnings call is scheduled for August 3.
W1
EBITDA margin sustainability above the 20% guided floor (this quarter ~24%) as the inventory build normalises
W2
Whether the ~55% revenue run-rate holds toward the 35–45% FY27 volume guide and ₹1,500 Cr FY28 target
W3
Pakhajan plant capex execution (₹125 Cr FY27) and the FY28 long-term contract commercialisation timeline
Clean digital filing, in ₹ Lakh (÷100 to Cr). No exceptional items either side. Consolidated revenue (₹307.7 Cr) sits BELOW standalone (₹314.1 Cr) — export sales lower at group level after consolidation of Yasho Europe B.V. & Yasho Inc.; consol PAT ₹36.05 Cr vs standalone ₹36.44 Cr. Subsidiaries added ₹23.46 Cr revenue but only ₹3.22 Cr net profit pre-adjustment. Year-ago (Q1 FY26) was a weak base (PAT ₹3.64 Cr), inflating YoY %.